Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2591-2601

  Coutant, Charles ^a,b,g   Rouzier, Roman ^b,g   Qi, Yuan ^a   Lehmann Che, Jacqueline ^c,h   Bianchini, Giampaolo ^a,d   Iwamoto, Takayuki ^a,e,i   Hortobagyi, Gabriel N ^a   Symmans, W Fraser ^a   Uzan, Serge ^b,g   Andre, Fabrice ^f   De The, Hugues ^c,h   Pusztai, Lajos ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c Université Paris Diderot Unité Mixte de Recherche 7212   (France)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e Department of Gastroenterological Surgery and Surgical Oncology ^*  (Japan)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; PROTEIN P53; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CHEMOSENSITIVITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79954612499     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1045     Document Type: Article

References (24)

1. Bertheau P, Turpin E, Rickman DS, Espiè M, de Reyniès A, Feugeas JP, et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 2007;4:e90.
2. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003;21:292-300.
3. Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-12. (Pubitemid 32685830)
4. Norberg T, Lennerstrand J, Inganas M, Bergh J. Comparison between p53 protein measurements using the luminometric immunoassay and immuno his to chemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer 1998;79:376-83. (Pubitemid 28359736)
5. Chappuis PO, Estreicher A, Dieterich B, Bonnefoi H, Otter M, Sappino AP, et al. Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay. Int J Cancer 1999;84:587-93.
6. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999;80:1968-73. (Pubitemid 29391282)
7. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
8. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
9. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74. (Pubitemid 32878711)
10. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23. (Pubitemid 36842560)
11. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D. P53 expression in breast cancer. Int J Cancer 1988;41:178-83. (Pubitemid 18061140)
12. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005;102:13550-5. (Pubitemid 41420886)
13. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029-34.
14. Dudoit S, Fridlyand J. A prediction-based resampling method for estimating the number of clusters in a dataset. Genome Biol 2002;3:RESEARCH0036.
15. Fronza G, Inga A, Monti P, Scott G, Campomenosi P, Menichini P, et al. The yeast p53 functional assay: a new tool for molecular epidemiology. Hopes and facts. Mutat Res 2000;462:293-301. (Pubitemid 30190235)
16. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation andclinical utility ofa70-geneprognostic signatureforwomen with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92. (Pubitemid 44390989)
17. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymphnodenegative primary breast cancer. Lancet 2005;365:671-9. (Pubitemid 40260888)
18. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, et al. Definition of clinically distinct molecular subtypes in estrogen receptorpositive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-46. (Pubitemid 46640570)
19. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
20. Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 2009;27:3185-91.
21. Jordan JJ, Inga A, Conway K, Edmiston S, Carey LA, Wu L, et al. Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. Mol Cancer Res 2010;8:701-16.
22. Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, Barbier CS, et al. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006;6:276.
23. Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptorpositive breast cancer. Clin Cancer Res 2007;13:2061-7. (Pubitemid 46649873)
24. Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, et al. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res 2010;70(21):8852-62.